Industriebank LIOF NV is a development and investment company based in Limburg, dedicated to enhancing the province's economic prosperity. It focuses on bolstering the local economy through its core activities, which include Acquisition, Participation, Development/Innovation, and the management of Business Parks. LIOF aims to attract and support the establishment of both domestic and foreign companies, provides venture capital to promising local businesses, and implements initiatives to enhance the competitiveness of Limburg's commercial landscape. Additionally, it coordinates the development of new business parks to create favorable conditions for growth. LIOF serves as a vital link between government entities and the business community, adopting a strategic approach that prioritizes long-term economic development. The organization is committed to understanding and addressing the needs of the business sector.
The SpecifAi Parking intelligence platform securely centralises and integrates parking data from numerous sources, presenting it in easy-to-understand dashboards. It leverages this information to provide predictive insights, allowing users to run their businesses more efficiently and effectively.
Mosa Meat
Venture Round in 2024
Mosa Meat B.V. is a food technology company based in Maastricht, the Netherlands, founded in 2013. The company specializes in the production of cultured meat by utilizing tissue engineering techniques. Mosa Meat harvests adult stem cells from the muscle tissue of living cows, allowing it to grow meat without the need for animal slaughter. This innovative process enables the production of products such as hamburgers and aims to reduce the environmental impact associated with traditional meat production. By creating real meat from animal cells, Mosa Meat contributes to a more sustainable food system, significantly lowering emissions, water usage, and land requirements while minimizing animal suffering.
Ansana
Seed Round in 2023
Ansana develops sterilization solutions for the pharmaceutical and healthcare industries. This technology is significantly cutting patient risk, reducing the environmental imprint, lowering expenses, and increasing flow.
Corporis
Series B in 2023
Corporis Medical is a medical device company focused on developing and commercializing innovative diagnostic tools for minimally invasive surgical procedures, particularly in laparoscopic and bowel surgery. The company aims to enhance surgical outcomes by preventing anastomotic leakages, allowing surgeons to assess the quality of the anastomosis during operations. By improving surgical techniques and outcomes, Corporis Medical contributes to reducing postoperative complications and lowering overall healthcare costs.
MLA Diagnostics
Venture Round in 2023
MLA Diagnostics is focused on developing a prognostic test, specifically the Ly75 indicator, which serves as a biomarker to predict clinical outcomes in patients with early-stage melanoma. This in vitro diagnostic method assesses a patient's metastatic risk, allowing healthcare providers to tailor treatment plans to individual needs. The test is characterized by its cost-effectiveness, reliability, and efficiency, facilitating informed decision-making between patients and physicians for more personalized treatment options that aim to improve overall patient well-being.
Embrosa
Seed Round in 2023
Emborosa is a company focused on streamlining marketing content distribution from brands to local retailers worldwide. It has developed a social media marketing platform aimed at simplifying the marketing process for local entrepreneurs. The platform offers a range of tools, including access to branded content, a monthly planning feature for Facebook, and personalized support. Additionally, Embrosa provides resources for beginners to help them effectively plan and manage their social media posts. By combining these elements, Embrosa enables users to create tailored marketing strategies that enhance their local presence.
ToxGenSolutions
Grant in 2022
ToxGenSolutions is a biotechnology company that specializes in developing diagnostic tools for preclinical diagnostics, particularly targeting Alzheimer's Disease. The company employs (epi-)genetic approaches to address molecular initiation events and key adverse outcome pathways associated with various pathologies, including neurodegeneration, cancer, and immune dysfunction. By focusing on mechanism-based genetic signatures, ToxGenSolutions aims to identify and classify new leads and toxicants during the drug screening and development process. This innovative approach enables healthcare professionals to intervene early in the disease progression, ultimately enhancing safety assessments and improving therapeutic strategies in drug development.
Aerial Precision
Seed Round in 2022
Aerial Precision specializes in designing and manufacturing advanced 3D sensing systems for commercial drones and mobile vehicles. The company focuses on light detection and ranging technology, which integrates sensors and artificial intelligence to deliver actionable insights derived from spatial data. Aerial Precision's systems create real-time three-dimensional maps, enhancing decision-making processes for clients by providing accessible and comprehensible drone data anytime and anywhere.
Neuroplast
Series B in 2021
Neuroplast is a biotechnology company that focuses on developing personalized neuro-regenerative medicine. The company aims to bring qualified autologous stem cell products to the global market, specifically targeting the treatment of spinal cord injuries, amyotrophic lateral sclerosis, and traumatic brain injuries. By isolating, manufacturing, and reinserting patients' own cells, Neuroplast enhances the potential for successful therapies that improve the quality of life for individuals suffering from these conditions. The company recognizes the need for dedicated standards and regulations in the field of neuro-regenerative medicine to ensure effective and safe treatment options.
Vertoro
Series A in 2021
Vertoro specializes in converting woody and agricultural residues into a diverse array of bio-based chemicals, materials, and fuels. The company produces crude lignin oil and crude sugar oil from these residues, providing a sustainable alternative to fossil resources. This bio-based oil serves as a liquid raw material for the petrochemical industry and offers a viable substitute for fossil crude oil in the production of various materials, chemicals, and fuels. By focusing on sustainable practices, Vertoro aims to deliver a universal biofuel source that supports the transition towards greener energy solutions.
Neuroplast
Funding Round in 2020
Neuroplast is a biotechnology company that focuses on developing personalized neuro-regenerative medicine. The company aims to bring qualified autologous stem cell products to the global market, specifically targeting the treatment of spinal cord injuries, amyotrophic lateral sclerosis, and traumatic brain injuries. By isolating, manufacturing, and reinserting patients' own cells, Neuroplast enhances the potential for successful therapies that improve the quality of life for individuals suffering from these conditions. The company recognizes the need for dedicated standards and regulations in the field of neuro-regenerative medicine to ensure effective and safe treatment options.
Vacis
Venture Round in 2019
Vacis is a leading tissue engineering company focused on developing innovative solutions for vascular surgery. The company specializes in creating in situ tissue-engineered blood vessels, addressing a significant challenge in the field: the frequent failure of prosthetic vascular grafts, which often leads to complications and increased healthcare costs. Vacis's technology employs a synthetic rod with a specialized surface, which, when inserted under the skin, stimulates the body to form a tissue capsule that matures into a functional blood vessel. This process allows for the creation of autologous graft vessels that offer sustained patency and reduce the need for corrective interventions, ultimately providing patients with safer and more effective options for vascular access, particularly in hemodialysis.
Paztir
Series A in 2019
Paztir specializes in automating vehicle and box locks while offering access management and tracking solutions for light electric vehicles. Its innovative system enhances traditional vehicles by integrating smart technology, allowing for automated locking and tracking capabilities. This technology is particularly beneficial for delivery companies, electric cargo bike manufacturers, and bike leasing firms, enabling them to optimize vehicle efficiency and improve operational performance. By implementing Paztir's solutions, customers can potentially save significant time daily per vehicle, enhance asset security, and gain valuable performance insights.
Grassa
Series A in 2019
Grassa BV specializes in the valorization of plant-based streams through bioraffinage, focusing on extracting value from grass and other agricultural residues. The company utilizes mobile refining machines to process fresh grass from pastures, agricultural by-products, invasive aquatic plants, and natural grass from conservation areas. This innovative approach yields four key products: fibers, protein, phosphate, and whey (liquid byproduct). Grassa's technology not only enhances the utility of these plant materials but also supports farmers by providing access to advanced solutions that help address food scarcity and improve their income stability.
Phenospex
Series A in 2018
Phenospex BV, located in Heerlen, the Netherlands, specializes in the development of a sensor platform and management system designed for the automated assessment of plant growth dynamics. The company provides digital solutions that capture and analyze crop data in conjunction with environmental factors, facilitating effective crop management. By offering advanced phenotyping technology, Phenospex enables seed companies, crop protection firms, and indoor farms to streamline their phenotyping processes into efficient, digital workflows. Their innovative approach amplifies the impact of agricultural practices and accelerates the development of sustainable agrochemicals and crops, ultimately contributing to the transition toward more sustainable agricultural methods.
Cristal Therapeutics
Venture Round in 2017
Cristal Therapeutics BV is a clinical-stage pharmaceutical company based in Maastricht, the Netherlands, founded in 2011. The company specializes in developing nanomedicines using its proprietary CriPec platform, which transforms drugs into nanoparticles for targeted therapy. This advanced technology aims to enhance the efficacy of both new and existing drugs by improving their delivery to specific tissues and cells, thereby addressing significant medical needs, particularly in cancer treatment. Cristal Therapeutics focuses on creating versatile nanomedicine solutions that can facilitate better outcomes in various therapeutic areas through innovative polymeric constructs.
Innosolids
Venture Round in 2015
Innosolids BV is a company based in Maastricht, Netherlands, specializing in the production and supply of various color solutions and additives for the plastics industry. Its product range includes pigments, masterbatch, liquid colors, compounds, and micro beats, as well as UV absorbers, heat stabilizers, antistatic products, flame retardants, nucleation agents, lubricants, and antioxidants. These products serve diverse applications across sectors such as sports and leisure, construction, automotive, and medical projects. Innosolids leverages proprietary technology to enhance the quality of plastic coloring while reducing costs and environmental impact. The company benefits from its proximity to the Brightland Campus, a hub for technological and chemical advancements, which supports its commitment to innovation in color development.
Quality Circular Polymers
Funding Round in 2014
Quality Circular Polymers specializes in providing high-quality circular polymer compounds derived from recycled plastics. The company focuses on sustainable recycling solutions for industrial waste, utilizing advanced compounding technology to transform used plastics into valuable materials. By developing an integrated recycling process, Quality Circular Polymers enables brand owners and plastics converters to reduce their reliance on fossil-based feedstock, thereby promoting a more sustainable approach to plastic use and waste management.
Ekompany
Venture Round in 2013
Ekompany is a Dutch producer of coated mineral fertilizers, specializing in Controlled Release Fertilizers (CRF) for agricultural and horticultural applications. Established in 2010, the company operates primarily in Western Europe and the Far East, with a production facility in Born that commenced operations in 2013. Ekompany employs a team of experts with extensive knowledge in the chemical and agricultural sectors, focusing on the design, production, and supply of specialty fertilizers. The company has developed a patented coating process that is cleaner, safer, and more energy-efficient than traditional methods, enabling the production of technologically advanced and cost-effective fertilizers. Their Ekote portfolio has demonstrated significant benefits through over 200 field trials conducted internationally, supporting sustainable agricultural practices.
Phenospex
Seed Round in 2011
Phenospex BV, located in Heerlen, the Netherlands, specializes in the development of a sensor platform and management system designed for the automated assessment of plant growth dynamics. The company provides digital solutions that capture and analyze crop data in conjunction with environmental factors, facilitating effective crop management. By offering advanced phenotyping technology, Phenospex enables seed companies, crop protection firms, and indoor farms to streamline their phenotyping processes into efficient, digital workflows. Their innovative approach amplifies the impact of agricultural practices and accelerates the development of sustainable agrochemicals and crops, ultimately contributing to the transition toward more sustainable agricultural methods.
MagnaMedics
Series B in 2011
MagnaMedics specializes in the engineering and production of magnetic nano- and microparticles designed for use in medical devices, drug delivery systems, and diagnostic kits. These particles facilitate the determination of biomarkers in body fluids, with a particular focus on proteomics. The company emphasizes high-quantity isolation of proteins, catering to researchers engaged in high-throughput screening of biomarkers. By providing innovative solutions, MagnaMedics enables manufacturers to conduct in-vitro diagnostics more efficiently and effectively.
FABPulous
Series A in 2010
FABPulous is a healthcare company based in The Netherlands, founded as a spin-off from Maastricht University in 2008. The company specializes in developing and marketing diagnostic solutions for primary care and emergency medicine. FABPulous has created a novel handheld disposable plasma separation device that enables rapid preparation of plasma from a drop of blood, facilitating point-of-care and home testing. This device can be integrated with various in vitro diagnostic platforms, such as lateral flow devices. The primary product under development is a rapid test for the cardiac biomarker heart-type fatty acid binding protein (H-FABP), which aids in the first-line diagnosis of acute myocardial infarction. By providing a simple and efficient diagnostic tool, FABPulous aims to enhance the speed and accuracy of medical assessments in critical care settings.
TiGenix
Private Equity Round in 2009
TiGenix NV is a Belgium-based biomedical company specializing in innovative treatments for damaged and osteoarthritic joints. Founded as a spin-off from the Catholic University of Leuven and the University of Ghent, TiGenix leverages regenerative medicine to create durable therapies validated through controlled clinical studies. The company focuses on developing a portfolio of products aimed at addressing specific musculoskeletal issues, with a primary emphasis on cartilage damage, which significantly impairs patient mobility and function. TiGenix also explores the anti-inflammatory properties of stem cells to create novel therapies for serious medical conditions, particularly in areas where there is a high unmet medical need.
Fortimedix
Venture Round in 2004
Fortimedix B.V., founded in 1999 and based in Nuth, the Netherlands, specializes in the development and manufacturing of endovascular, coronary, and peripheral stents. As a global leader in stent technology, the company has established a strong presence in the medical device industry, focusing on innovation and continuous improvement. With full in-house capabilities for stent development and production, Fortimedix is dedicated to operational excellence. The company prioritizes research and development to advance its technology and meet the evolving needs of its customers and stakeholders.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.